Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
| Revenue (TTM) | $31.98M |
| Gross Profit (TTM) | $31.82M |
| EBITDA | $-57.64M |
| Operating Margin | -25405.00% |
| Return on Equity | -397.30% |
| Return on Assets | -45.70% |
| Revenue/Share (TTM) | $0.54 |
| Book Value | $0.32 |
| Price-to-Book | 18.42 |
| Price-to-Sales (TTM) | 11.18 |
| EV/Revenue | 8.82 |
| EV/EBITDA | -1.81 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.50% |
| Shares Outstanding | $60.10M |
| Float | $32.95M |
| % Insiders | 24.45% |
| % Institutions | 47.66% |
Volatility is currently contracting
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy ("AVIM Therapy") will be featured in two sessions at HRX Live 2026 -- the Heart Rhythm Society's annual innovation-focused meeting taking place September 18-20, 2026, in Atlanta, Georgia.
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides additional capital to advance Orchestra BioMed's pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of $6.1 million on September 14, 2026, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”).
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 133,000 shares of the Company's common stock to seven newly hired employees.
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the H.C.
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, Sept. 10, 2026 at 1:30pm ET and will also host one-on-one meetings with investors that day and on Wednesday, Sept. 9.
Orchestra BioMed is approaching pivotal trial readouts for AVIM Therapy and Virtue SAB, both with strong success potential. OBIO operates as an innovation and clinical development platform for medical devices, relying on Medtronic and Terumo for commercialization. Medtronic and Terumo have invested a combined $146 million, with OBIO's $220 million valuation reflecting a modest premium to strategic funding and with significant potential upside as catalysts approach.
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026.
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on June 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 85,500 shares of the Company's common stock to five newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.
NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will be participating in the Jefferies Global Healthcare Conference.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OBIO and any ticker you trade — then tracks every position and per-strategy win rate.
